With First Drug Approved, Intercept Taps Kapadia As New CFO

Intercept Pharmaceuticals (NASDAQ: [[ticker:ICPT]]) of New York has a new product on the market, its first, with last month’s approval of obeticholic acid (Ocaliva) to treat a rare liver disease. Now it also has a new CFO. Sandip Kapadia, a veteran of Swiss drug giant Novartis, will take over for Barbara Duncan on July 1, Intecept announced. Duncan is stepping down after seven years at the post. Kapadia was most recently CFO of the North American unit of Sandoz, the Novartis generic drug division.

Author: Alex Lash

I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and Xconomy. View all posts by Alex Lash